CYP24A1 is overexpressed in keloid keratinocytes and its inhibition alters profibrotic gene expression

Abstract

Background: Keloids are disfiguring, fibrotic scar-like lesions that are challenging to treat and commonly recur after therapy. A deeper understanding of the mechanisms driving keloid formation is necessary for the development of more effective therapies. Reduced vitamin D receptor (VDR) expression has been observed in keloids, implicating vitamin D signaling in keloid pathology. Vitamin D exhibits anti-proliferative and anti-inflammatory properties, suggesting it could have therapeutic utility in keloid disorder. The current study investigated vitamin D-regulated gene expression in keloid keratinocytes and the effects of inhibiting an enzyme involved in vitamin D metabolism on the phenotype of keloid-derived keratinocytes. Methods: Normal and keloid-derived primary keratinocytes were isolated from normal skin and keloid lesions, respectively, and were cultured in the absence or presence of vitamin D. In some experiments, inhibitors of the vitamin D metabolizing enzyme CYP24A1, ketoconazole or VID400 were added in the absence or presence of vitamin D. Cellular proliferation, migration and gene expression were measured. Results: We observed significant overexpression of CYP24A1 mRNA in keloid versus normal keratinocytes and increased CYP24A1 protein levels in keloids versus normal skin. CYP24A1 encodes 24 hydroxylase and is induced by vitamin D in a feedback loop that regulates vitamin D levels; thus, inhibition of CYP24A1 activity may locally increase active vitamin D levels. Ketoconazole, a non-specific cytochrome P-450 inhibitor, reduced proliferation of keloid and normal keratinocytes, but VID400, a specific CYP24A1 inhibitor, only significantly affected keloid keratinocyte proliferation. Neither inhibitor significantly reduced keratinocyte migration. The two inhibitors had different effects on vitamin D target gene expression in keratinocytes. Specifically, ketoconazole treatment reduced CYP24A1 expression in normal and keloid keratinocytes, whereas VID400 increased CYP24A1 expression. Both inhibitors decreased expression of profibrotic genes, including periostin and hyaluronan synthase 2, in keloid-derived cells. Combined treatment of keloid keratinocytes with vitamin D and ketoconazole or VID400 increased the effects of vitamin D treatment on target genes, although the effects were gene-and cell type-specific. Conclusions: The data suggest that reduction of vitamin D inactivation with CYP24A1 inhibitors may reduce profibrotic gene expression in keloid-derived cells. Therefore, CYP24A1 inhibitors may serve as adjunctive therapies to suppress keloid-associated gene expression changes.

Keywords

Keloid / Keratinocyte / Vitamin D / CYP24A1 / 24-hydroxylase / Epithelial-mesenchymal transition

References

[1] Limandjaja GC, Niessen FB, Scheper RJ, Gibbs S. The keloid disorder: heterogeneity, histopathology, mechanisms and models. Front Cell Dev Biol 2020; 8: 360. https://doi.org/10.3389/fcell.2020.00360.

[2] Stone RC, Chen V, Burgess J, Pannu S, Tomic-Canic M. Genomics of human fibrotic diseases: disordered wound healing response. Int J Mol Sci 2020; 21: 8590. https://doi.org/10.3390/ijms21228590.

[3] Tan A, Glass DA 2nd. Patient-reported outcomes for keloids: a systematic review. G Ital Dermatol Venereol 2019; 154: 148-65. https://doi.org/10.23736/S0392-0488.18.06089-3.

[4] Bijlard E, Kouwenberg CA, Timman R, Hovius SE, Busschbach JJ, Mureau MA. Burden of keloid disease: a cross-sectional health-related quality of life assessment. Acta Derm Venereol 2017; 97: 225-9. https://doi.org/10.2340/00015555-2498.

[5] Al Zahrani RA, Alotaibi WN, Almanasef ZM, Malawi I, Mohammed LA, Algahamdi RA. et al. Comprehensive analysis of current treatment approaches for keloids in pediatrics: a systematic review. Cureus 2023; 15: e50290. https://doi.org/10.7759/cureus.50290.

[6] Qi W, Xiao X, Tong J, Guo N. Progress in the clinical treatment of keloids. Front Med 2023; 10: 1284109. https://doi.org/10.3389/fmed.2023.1284109.

[7] Wang ZC, Zhao WY, Cao Y, Liu YQ, Sun Q, Shi P. et al. The roles of inflammation in keloid and hypertrophic scars. Front Immunol 2020; 11: 603187. https://doi.org/10.3389/fimmu.2020.603187.

[8] Chen W, Fu X, Sun X, Sun T, Zhao Z, Sheng Z. Analysis of differentially expressed genes in keloids and normal skin with cDNA microarray. J Surg Res 2003; 113: 208-16. https://doi.org/10.1016/S0022-4804(03)00188-4.

[9] Naitoh M, Kubota H, Ikeda M, Tanaka T, Shirane H, Suzuki S, Nagata K. Gene expression in human keloids is altered from dermal to chondrocytic and osteogenic lineage. Genes Cells 2005; 10: 1081-91. https://doi.org/10.1111/j.1365-2443.2005.00902.x.

[10] Smith JC, Boone BE, Opalenik SR, Williams SM, Russell SB. Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. J Invest Dermatol 2007; 128: 1298-310. https://doi.org/10.1038/sj.jid.5701149.

[11] Seifert O, Bayat A, Geffers R, Dienus K, Buer J, Lofgren S, Matussek A. Identification of unique gene expression patterns within different lesional sites of keloids. Wound Repair Regen 2008; 16: 254-65. https://doi.org/10.1111/j.1524-475X.2007.00343.x.

[12] Hahn JM, Glaser K, McFarland KL, Aronow BJ, Boyce ST, Supp DM. Keloid-derived keratinocytes exhibit an abnormal gene expression profile consistent with a distinct causal role in keloid pathology. Wound Repair Regen 2013; 21: 530-44. https://doi.org/10.1111/wrr.12060.

[13] Cohen AJ, Nikbakht N, Uitto J. Keloid disorder: genetic basis, gene expression profiles, and immunological modulation of the fibrotic processes in the skin. Cold Spring Harb Perspect Biol 2023; 15:a041245. https://doi.org/10.1101/cshperspect.a041245.

[14] Macarak EJ, Wermuth PJ, Rosenbloom J, Uitto J. Keloid disorder: fibroblast differentiation and gene expression profile in fibrotic skin diseases. Exp Dermatol 2021; 30: 132-45. https://doi.org/10.1111/exd.14243.

[15] Slemp AE, Kirschner RE. Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. Curr Opin Pediatr 2006; 18: 396-402. https://doi.org/10.1097/01.mop.0000236389.41462.ef.

[16] Davis SA, Feldman SR, McMichael AJ. Management of keloids in the United States, 1990-2009: an analysis of the National Ambulatory Medical Care Survey. Dermatologic Surg 2013; 39: 988-94. https://doi.org/10.1111/dsu.12182.

[17] Velez Edwards DR, Tsosie KS, Williams SM, Edwards TL, Russell SB. Admixture mapping identifies a locus at 15q21.2-22.3 associated with keloid formation in African Americans. Hum Genet 2014; 133: 1513-23. https://doi.org/10.1007/s00439-014-1490-9.

[18] Tirgan M. Massive ear keloids: natural history, evaluation of risk factors and recommendation for preventive measures-a retrospective case series. F1000 Res 2016; 5: 2517. https://doi.org/10.12688/f1000research.9504.1.

[19] Sadiq A, Khumalo NP, Bayat A. 2020. Genetics of keloid scarring. In Téot L, Mustoe TA, Middelkoop E. et al. (eds).Textbook on Scar Management: State of the Art Management and Emerging Technologies. Cham (CH): Springer; Copyright 2020, The Author(s). 61-76.

[20] Matsuoka LY, Wortsman J, Haddad JG, Kolm P, Hollis BW. Racial pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol 1991; 127: 536-8. https://doi.org/10.1001/archderm.1991.04510010104011.

[21] Clemens TL, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982; 319: 74-6. https://doi.org/10.1016/S0140-6736(82)90214-8.

[22] Shieh A, Aloia JF. Assessing vitamin D status in African Americans and the influence of vitamin D on skeletal health parameters. Endocrinol Metab Clin N Am 2017; 46: 135-52. https://doi.org/10.1016/j.ecl.2016.09.006.

[23] Yu D, Shang Y, Luo S, Hao L. The TaqI gene polymorphisms of VDR and the circulating 1,25-dihydroxyvitamin D levels confer the risk for the keloid scarring in Chinese cohorts. Cell Physiol Biochem 2013; 32: 39-45. https://doi.org/10.1159/000350121.

[24] El Hadidi HH, Sobhi RM, Nada AM, AbdelGhaffar MMM, Shaker OG, El-Kalioby M. Does vitamin D deficiency predispose to keloids via dysregulation of koebnerisin (S100A15)? A case-control study. Wound Repair Regen 2021; 29: 425-31. https://doi.org/10.1111/wrr.12894.

[25] Damanik VI, Putra IB, Ginting O. Correlation between serum 25-hydroxyvitamin D levels with keloid severity. Open Access Maced J Med Sci 2019; 7: 65-7. https://doi.org/10.3889/oamjms.2019.022.

[26] Bikle DD. The vitamin D receptor: a tumor suppressor in skin. Discov Med 2011; 11: 7-17.

[27] Wimalawansa SJ. Non-musculoskeletal benefits of vitamin D. J Steroid Biochem Mol Biol 2018; 175: 60-81. https://doi.org/10.1016/j.jsbmb.2016.09.016.

[28] Shany S, Sigal-Batikoff I, Lamprecht S. Vitamin D and myofibroblasts in fibrosis and cancer: At cross-purposes with TGF-beta/SMAD signaling. Anticancer Res 2016; 36: 6225-34. https://doi.org/10.21873/anticanres.11216.

[29] Subramaniam N, Leong GM, Cock TA, Flanagan JL, Fong C, Eisman JA, Kouzmenko AP. Cross-talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem 2001; 276: 15741-6. https://doi.org/10.1074/jbc.M011033200.

[30] Lin R. Crosstalk between vitamin D metabolism, VDR signalling, and innate immunity. Biomed Res Int 2016; 2016: 1-5. https://doi.org/10.1155/2016/1375858.

[31] Vergara D, Catherino WH, Trojano G, Tinelli A.Vitamin D: mechanism of action and biological effects in uterine fibroids. Nutrients 2021; 13: 597. https://doi.org/10.3390/nu13020597.

[32] Larriba MJ, Garcia de HA, Munoz A. Vitamin D and the epithelial to mesenchymal transition. Stem Cells Int 2016; 2016: 6213872. https://doi.org/10.1155/2016/6213872.

[33] Hahn JM, McFarland KL, Combs KA, Supp DM. Partial epithelial-mesenchymal transition in keloid scars: regulation of keloid keratinocyte gene expression by transforming growth factor-β1. Burns Trauma 2016; 4: 30. https://doi.org/10.1186/s41038-016-0055-7.

[34] Kuwahara H, Tosa M, Egawa S, Murakami M, Mohammad G, Ogawa R. Examination of epithelial mesenchymal transition in keloid tissues and possibility of keloid therapy target. Plast Reconstr Surg Glob Open 2016; 4: e1138. https://doi.org/10.1097/GOX.0000000000001138.

[35] Vu R, Dragan M, Sun P, Werner S, Dai X. Epithelial-mesenchymal plasticity and endothelial-mesenchymal transition in cutaneous wound healing. Cold Spring Harb Perspect Biol 2023; 15:a041237. https://doi.org/10.1101/cshperspect.a041237.

[36] Supp DM, Hahn JM, McFarland KL, Glaser K. Inhibition of hyaluronan synthase 2 reduces the abnormal migration rate of keloid keratinocytes. J Burn Care Res 2014; 35: 84-92. https://doi.org/10.1097/BCR.0b013e3182a2a9dd.

[37] Hahn JM, Supp DM. Abnormal expression of the vitamin D receptor in keloid scars. Burns 2017; 43: 1506-15. https://doi.org/10.1016/j.burns.2017.04.009.

[38] Xie Z, Munson SJ, Huang N, Portale AA, Miller WL, Bikle DD. The mechanism of 1,25-dihydroxyvitamin D(3) autoregulation in keratinocytes. J Biol Chem 2002; 277: 36987-90. https://doi.org/10.1074/jbc.M201404200.

[39] Muindi JR, Yu WD, Ma Y, Engler KL, Kong RX, Trump DL, Johnson CS. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 2010; 151: 4301-12. https://doi.org/10.1210/en.2009-1156.

[40] Gröschel C, Tennakoon S, Kállay E. Cytochrome P450 vitamin D hydroxylases in inflammation and cancer. Adv Pharmacol 2015; 74: 413-58. https://doi.org/10.1016/bs.apha.2015.03.002.

[41] Kamiya S, Nakamori Y, Takasawa A, Takasawa K, Kyuno D, Ono Y. et al. Vitamin D metabolism in cancer: potential feasibility of vitamin D metabolism blocking therapy. Med Mol Morphol 2023; 56: 85-93. https://doi.org/10.1007/s00795-023-00348-x.

[42] King AN, Beer DG, Christensen PJ, Simpson RU, Ramnath N. The vitamin D/CYP24A1 story in cancer. Anti Cancer Agents Med Chem 2010; 10: 213-24. https://doi.org/10.2174/1871520611009030213.

[43] Supp DM, Hahn JM, Combs KA, McFarland KL, Powell HM. Isolation and feeder-free primary culture of four cell types from a single human skin sample. STAR Protoc 2022; 3: 101172. https://doi.org/10.1016/j.xpro.2022.101172.

[44] Supp DM, Hahn JM, Lloyd CM, Combs KA, Swope VB, Abdel-Malek Z, Boyce ST. Light or dark pigmentation of engineered skin substitutes containing melanocytes protects against ultraviolet light-induced DNA damage in vivo. J Burn Care Res 2020; 41: 751-60. https://doi.org/10.1093/jbcr/iraa029.

[45] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25: 402-8. https://doi.org/10.1006/meth.2001.1262.

[46] Koivisto O, Hanel A, Carlberg C. Key vitamin D target genes with functions in the immune system. Nutrients 2020; 12: 1140. https://doi.org/10.3390/nu12041140.

[47] Luo W, Hershberger PA, Trump DL, Johnson CS. 24-Hydroxylase in cancer: impact on vitamin D-based anticancer therapeutics. J Steroid Biochem Mol Biol 2013; 136: 252-7. https://doi.org/10.1016/j.jsbmb.2012.09.031.

[48] Reinhardt TA, Horst RL. Ketoconazole inhibits self-induced metabolism of 1,25-dihydroxyvitamin D3 and amplifies 1,25-dihydroxyvitamin D3 receptor up-regulation in rat osteosarcoma cells. Arch Biochem Biophys 1989; 272: 459-65. https://doi.org/10.1016/0003-9861(89)90240-3.

[49] Ferla S, Gomaa MS, Brancale A, Zhu J, Ochalek JT, DeLuca HF, Simons C. Novel styryl-indoles as small molecule inhibitors of 25-hydroxyvitamin D-24-hydroxylase (CYP24A1): synthesis and biological evaluation. Eur J Med Chem 2014; 87: 39-51. https://doi.org/10.1016/j.ejmech.2014.09.035.

[50] Schuster I, Egger H, Bikle D, Herzig G, Reddy GS, Stuetz A. et al. Selective inhibition of vitamin D hydroxylases in human keratinocytes. Steroids 2001; 66: 409-22. https://doi.org/10.1016/S0039-128X(00)00159-8.

[51] Kang S, Li XY, Duell EA. et al. The retinoid X receptor agonist 9-cis-retinoic acid and the 24-hydroxylase inhibitor ketoconazole increase activity of 1,25-dihydroxyvitamin D3 in human skin in vivo. J Invest Dermatol 1997; 108: 513-8. https://doi.org/10.1111/1523-1747.ep12289736.

[52] Banecki K, Dora KA. Endothelin-1 in health and disease. Int J Mol Sci 2023; 24: 11295. https://doi.org/10.3390/ijms241411295.

[53] Jain R, Shaul PW, Borok Z, Willis BC. Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type a receptor-mediated production of TGF-beta1. Am J Respir Cell Mol Biol 2007; 37: 38-47. https://doi.org/10.1165/rcmb.2006-0353OC.

[54] Rosanò L, Spinella F, Di Castro V, Decandia S, Nicotra MR, Natali PG, Bagnato A. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Exp Biol Med 2006; 231: 1128-31.

[55] Wu MH, Huang PH, Hsieh M, Tsai CH, Chen HT, Tang CH. Endothelin-1 promotes epithelial-mesenchymal transition in human chondrosarcoma cells by repressing miR-300. Oncotarget 2016; 7: 70232-46. https://doi.org/10.18632/oncotarget.11835.

[56] Kiya K, Kubo T, Kawai K, Matsuzaki S, Maeda D, Fujiwara T. et al. Endothelial cell-derived endothelin-1 is involved in abnormal scar formation by dermal fibroblasts through RhoA/Rho-kinase pathway. Exp Dermatol 2017; 26: 705-12. https://doi.org/10.1111/exd.13264.

[57] Yin P, Bai Y, Wang Z, Sun Y, Gao J, Na L. et al. Non-canonical Fzd7 signaling contributes to breast cancer mesenchymal-like stemness involving Col6a1. Cell Commun Signal 2020; 18: 143. https://doi.org/10.1186/s12964-020-00646-2.

[58] Calanca N, Binato SMS, da Silva SD, Brentani HP, Sennes LU, Pinto CAL. et al. Master regulators of epithelial-mesenchymal transition and Wnt signaling pathways in juvenile nasopharyngeal angiofibromas. Biomedicines 2021; 9: 1258. https://doi.org/10.3390/biomedicines9091258.

[59] Lee DE, Trowbridge RM, Ayoub NT, Agrawal DK. High-mobility group box protein-1, matrix metalloproteinases, and vitamin D in keloids and hypertrophic scars. Plast Reconstr Surg Glob Open 2015; 3: e425. https://doi.org/10.1097/GOX.0000000000000391.

[60] Zhou HM, Wang J, Elliott C, Wen W, Hamilton DW, Conway SJ. Spatiotemporal expression of periostin during skin development and incisional wound healing: lessons for human fibrotic scar formation. J Cell Commun Signal 2010; 4: 99-107. https://doi.org/10.1007/s12079-010-0090-2.

[61] Gong ZH, Ji JF, Yang J, Xiang T, Zhou CK, Pan XL, Yao J. Association of plasminogen activator inhibitor-1 and vitamin D receptor expression with the risk of keloid disease in a Chinese population. Kaohsiung J Med Sci 2017; 33: 24-9. https://doi.org/10.1016/j.kjms.2016.10.013.

[62] Larriba MJ, Gonzalez-Sancho JM, Barbachano A, Niell N, Ferrer-Mayorga G, Munoz A. Vitamin D is a multilevel repressor of Wnt/b-catenin signaling in cancer cells. Cancers 2013; 5: 1242-60. https://doi.org/10.3390/cancers5041242.

[63] Zheng S, Yang J, Hu X, Li M, Wang Q, Dancer RCA. et al. Vitamin D attenuates lung injury via stimulating epithelial repair, reducing epithelial cell apoptosis and inhibits TGF-beta induced epithelial to mesenchymal transition. Biochem Pharmacol 2020; 177: 113955. https://doi.org/10.1016/j.bcp.2020.113955.

[64] Peleg S, Nguyen CV. The importance of nuclear import in protection of the vitamin D receptor from polyubiquitination and proteasome-mediated degradation. J Cell Biochem 2010; 110: 926-34. https://doi.org/10.1002/jcb.22606.

[65] Kongsbak M, von Essen MR, Boding L, Levring TB, Schjerling P, Lauritsen JP. et al. Vitamin D up-regulates the vitamin D receptor by protecting it from proteasomal degradation in human CD4+ T cells. PLoS One 2014; 9: e96695. https://doi.org/10.1371/journal.pone.0096695.

[66] Li XY, Boudjelal M, Xiao JH, Ping ZH, Asuru A, Kang S. et al. 1,25-Dihydroxyvitamin D3 increases nuclear vitamin D3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin. Mol Endocrinol 1999; 13: 1686-94. https://doi.org/10.1210/mend.13.10.0362.

[67] Muralidhar S, Filia A, Nsengimana J, Pozniak J, O’Shea SJ, Diaz JM. et al. Vitamin D-VDR signaling inhibits Wnt/beta-catenin-mediated melanoma progression and promotes antitumor immunity. Cancer Res 2019; 79: 5986-98. https://doi.org/10.1158/0008-5472.CAN-18-3927.

[68] He B, Stoffel L, He CJ, Cho K, Li AM, Jiang H. et al. Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma towards a vitamin D susceptible state. Cell Death Dis 2024; 15: 89. https://doi.org/10.1038/s41419-024-06460-9.

[69] Li Y, Cook KL, Yu W, Jin L, Bouker KB, Clarke R, Hilakivi-Clarke L. Inhibition of antiestrogen-promoted pro-survival autophagy and tamoxifen resistance in breast cancer through vitamin D receptor. Nutrients 2021; 13: 1715. https://doi.org/10.3390/nu13051715.

[70] Negri M, Gentile A, de Angelis C, Monto T, Patalano R, Colao A. et al. Vitamin D-induced molecular mechanisms to potentiate cancer therapy and to reverse drug-resistance in cancer cells. Nutrients 2020; 12: 1798. https://doi.org/10.3390/nu12061798.

[71] Zheng W, Duan B, Zhang Q, Ouyang L, Peng W, Qian F. et al. Vitamin D-induced vitamin D receptor expression induces tamoxifen sensitivity in MCF-7 stem cells via suppression of Wnt/β-catenin signaling. Biosci Rep 2018; 38: BSR20180595.

[72] Zineb R, Zhor B, Odile W, Marthe RR. Distinct, tissue-specific regulation of vitamin D receptor in the intestine, kidney, and skin by dietary calcium and vitamin D. Endocrinology 1998; 139: 1844-52. https://doi.org/10.1210/endo.139.4.5903.

[73] Cabalín C, Pérez-Mateluna G, Iturriaga C, Camargo CA Jr, Borzutzky A. Oral vitamin D modulates the epidermal expression of the vitamin D receptor and cathelicidin in children with atopic dermatitis. Arch Dermatol Res 2023; 315: 761-70. https://doi.org/10.1007/s00403-022-02416-1.

[74] Peroni DG, Piacentini GL, Cametti E, Chinellato I, Boner AL. Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in children. Br J Dermatol 2011; 164: 1078-82. https://doi.org/10.1111/j.1365-2133.2010.10147.x.

[75] Wu Y, Gong Y, Ma Y, Zhao Q, Fu R, Zhang X. et al. Effects of vitamin D status on cutaneous wound healing through modulation of EMT and ECM. J Nutr Biochem 2024; 134: 109733. https://doi.org/10.1016/j.jnutbio.2024.109733.

[76] Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 2006; 57: 234-40. https://doi.org/10.1007/s00280-005-0059-7.

[77] Russo B, Brembilla NC, Chizzolini C. Interplay between keratinocytes and fibroblasts: a systematic review providing a new angle for understanding skin fibrotic disorders. Front Immunol 2020; 11: 648. https://doi.org/10.3389/fimmu.2020.00648.

[78] Gauglitz GG, Bureik D, Zwicker S, Ruzicka T, Wolf R. The antimicrobial peptides psoriasin (S100A7) and koebnerisin (S100A15) suppress extracellular matrix production and proliferation of human fibroblasts. Skin Pharmacol Physiol 2015; 28: 115-23. https://doi.org/10.1159/000363579.

[79] Zhao J, Zhong A, Friedrich EE, Jia S, Xie P, Galiano RD. et al. S100A12 induced in the epidermis by reduced hydration activates dermal fibroblasts and causes dermal fibrosis. J Invest Dermatol 2017; 137: 650-9. https://doi.org/10.1016/j.jid.2016.10.040.

[80] Zhong A, Xu W, Zhao J, Xie P, Jia S, Sun J. et al. S100A8 and S100A9 are induced by decreased hydration in the epidermis and promote fibroblast activation and fibrosis in the dermis. Am J Pathol 2016; 186: 109-22. https://doi.org/10.1016/j.ajpath.2015.09.005.

[81] Lim IJ, Phan TT, Song C, Tan WTL, Longaker MT. Investigation of the influence of keloid-derived keratinocytes on fibroblast growth and proliferation in vitro. Plast Reconstruct Surg 2001; 107: 797-808. https://doi.org/10.1097/00006534-200103000-00022.

[82] Lim IJ, Phan TT, Bay BH, Qi R, Huynh H, Tan WT. et al. Fibroblasts cocultured with keloid keratinocytes: normal fibroblasts secrete collagen in a keloidlike manner. Am J Cell Physiol 2002; 283: C212-22. https://doi.org/10.1152/ajpcell.00555.2001.